Experienced in Essential Thrombocythemia

Jurgen H. Finke

Hugstetter Str. 55, 
Freiburg, BW, DE 
Experienced in Essential Thrombocythemia
Hugstetter Str. 55, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Jurgen Finke practices in Freiburg, Germany. Finke is rated as an Experienced expert by MediFind in the treatment of Essential Thrombocythemia. Their top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 327 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Essential Thrombocythemia.

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany
Other Locations
Volkmaroder Str. 5, Braunschweig, NI 38104, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

327 Total Publications

Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study.
Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study.
Journal: Bone marrow transplantation
Published: May 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Finke's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile